Eupraxia Reports Durable 52-Week Symptom Relief With EP-104GI in Eosinophilic Esophagitis Trial

Reuters · 11/13/2025 22:00

Please log in to view news
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.